Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies

NCT04088890 is registered in ClinicalTrials.gov with Matthew Frank as lead sponsor.

NCT NCT04088890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04088890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies
Lead sponsor
Matthew Frank
Phase
Phase 1
Overall status
Completed
Start date
September 12, 2019
Completion date
March 7, 2025
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-all, b-cell non hodgkin lymphoma, dlbcl, follicular lymphoma grade 3b